SAS Output

23-FEB-2019 6:10

BREAST ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9400 9383 0 0 0 0 0 02/28/2011 378 177
            9383 0 0 0 0 0      
 
    2 Y 2 Chemo and Endocrine Therapy 5000 2547 0 0 0 0 0 02/28/2011    
        3 Endocrine Therapy Alone   2536 0 0 0 0 0      
            5083 0 0 0 0 0      
 
  S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 1900 925 175 90 42 17 3 09/12/2013 441 205
        2 Blinded drug + Endocrine   931 168 84 40 14 1      
            1856 343 174 82 31 4      
 
  S1222-Brst,Fulv. +/- Ever. +/- Anastr. 1 T 1 Blinded treatment 840 12 0 0 0 0 0 05/15/2014 13 3
        2 Blinded treatment   12 0 0 0 0 0      
        3 Blinded treatment   13 0 0 0 0 0      
            37 0 0 0 0 0      
 
  S1416-Brst, TNBC/BRCA, Cis+/- ABT-888 1 Y 1 Blinded Drug + Cisplatin 333 149 39 23 14 2 0 09/15/2016 292 150
        2 Blinded Drug + Cisplatin   152 41 28 12 4 1      
            301 80 51 26 6 1      
 
  S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 1000 451 290 155 90 33 5 01/18/2017 479 210
            451 290 155 90 33 5      
 
    2 Y 2 Observation 1000 193 125 65 38 16 5 01/18/2017    
        3 MK-3475 (Pembrolizumab)   187 119 63 36 14 3      
            380 244 128 74 30 8      
 
  S1706-Breast, Inflammatory, RT +/- Olaparib 1 Y 1 Olaparib + RT 300 1 1 1 1 0 0 01/18/2019 123 56
        2 RT   1 1 1 1 1 0      
            2 2 2 2 1 0      
 
Yes A011106-Breast, Neoadj, ALTERNATE study 1 E Total Registrations   85 32 11 5 2 0 04/29/2014   114
            85 32 11 5 2 0      
 
  E1Z11-Brst,Genetic Predictors of AIMSS 1 E Total Registrations   156 7 3 0 0 0 08/13/2013   11
            156 7 3 0 0 0      
 
  NRGBR003-Brst,Adj,TNBC,AC -> WP +/- Carbo 1 E Total Registrations   69 21 10 3 0 0 10/16/2015   173
            69 21 10 3 0 0      
 
  NRGBR005-Br, Stg II&IIIA, Post NAdj Chemo Br Conserv 1 E Total Registrations   6 6 4 2 0 0 06/22/2018 144 78
            6 6 4 2 0 0      
 
No A011401-Breast, adj, Stage II/III HER2-, weight loss 1 E Total Registrations   213 102 41 21 8 2 10/05/2016   246
            213 102 41 21 8 2      
 
    2 E Total Registrations   193 96 36 17 6 3 10/05/2016    
            193 96 36 17 6 3      
 
  A011502-Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 1 E Total Registrations   78 51 28 17 7 1 03/20/2017 488 260
            78 51 28 17 7 1      
 
  A221405-Breast, ET interruption, Pregnancy Outcomes 1 E Total Registrations   13 5 1 0 0 0 05/08/2017 132 55
            13 5 1 0 0 0      
 
  B51-Breast, Regional Nodal XRT 1 E Total Registrations   33 8 4 1 0 0 06/13/2014   170
            33 8 4 1 0 0      
 
  B55-Brst, Adj Olaparib for BRCA,TNBC 1 E Total Registrations   70 18 5 2 2 1 12/15/2014 440 185
            70 18 5 2 2 1      
 
    2 E Total Registrations   33 10 2 1 1 0 12/15/2014    
            33 10 2 1 1 0      
 
  EA1131-Brst, TNBC, Post-op Chemo vs Obs 0 E Total Registrations   27 11 9 4 3 0 11/12/2015   132
            27 11 9 4 3 0      
 
    1 P Total Registrations   14 6 3 3 0 0 11/12/2015    
            14 6 3 3 0 0      
 
  EA1151-Brst, Tomosynthesis Mammographic Screening 1 E Total Registrations   324 313 154 84 41 7 01/30/2018 147 72
            324 313 154 84 41 7      
 
  NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA 1 E Total Registrations   1 0 0 0 0 0 09/22/2017 322 141
            1 0 0 0 0 0